Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24214 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL7715839 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL1356717 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL5448 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL6654323 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15952 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3690123 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL3834 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL10262394 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE | |
| SCHEMBL15665811 | 1.00 | PRKCA (0.52) | PRKCAMAPTMAPK1LMNAPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100183-A1 | COMPOSITIONS COMPRISING MOLECULES FOR CYSTIC FIBROSIS TREATMENT | NATIONAL INSTITUTES OF HEALTH | 2024-03-28 | — | — | US | disclosed |
| US-20180057542-A1 | THERAGNOSTIC PARTICLES | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2018-03-01 | — | — | US | disclosed |
| US-9844578-B2 | Accelerated healing of eye injuries by angiotensin peptides | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-12-19 | — | — | US | disclosed |
| US-8088395-B2 | Phytol derived immunoadjuvants and their use in vaccine formulations | INDIANA STATE UNIVERSITY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | INDIANA STATE UNIVERSITY | 2006-12-28 | — | — | US | disclosed |
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | GHOSH SWAPAN K (US) | 2005-07-21 | — | — | US | disclosed |
| EP-0975331-A1 | A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS | DUMEX-ALPHARMA A/S (DK) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047487-A1 | A NOVEL BIOADHESIVE DRUG DELIVERY SYSTEM BASED ON LIQUID CRYSTALS | DUMEX-ALPHARMA A/S (DK) | 1998-10-29 | — | — | WO | disclosed |
| EP-0398478-A1 | Temperature release containers | STUART SHELDON BOWIE (US) | 1990-11-22 | — | — | EP | disclosed |
| US-4216295-A | Foamable resole resin composition | MONSANTO COMPANY (US) | 1980-08-05 | — | — | US | disclosed |
| US-4207401-A | CONTAINING DISPERION OF CALCIUM OXIDE PARITCLES | MONSANTO COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4207400-A | ZINC, IRON, MAGNESIUM, CALCIUM, BARIUM | MONSANTO COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050158329-A1 | Novel phytol derived immunoadjuvants and their use in vaccine formulations | CD47, TSG101, LY96 | PRKCA 1302/4885MAPT 1634/4885MAPK1 1422/4885 |
| US-20060292163-A1 | PHYTOL DERIVED IMMUNOADJUVANTS AND THEIR USE IN VACCINE FORMULATIONS | CD47, LY96, CD4 | PRKCA 1113/4885MAPT 1249/4885MAPK1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.